Marshall Wace
PYXS icon

Marshall Wace’s Pyxis Oncology PYXS Stock Holding History

Marshall Wace’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$517K Sell
354,417
-35,347
-9% -$53.3K ﹤0.01% 2436
2025
Q4 		$448K Buy
+389,764
New +$1.37M ﹤0.01% 2282
2025
Q3 		– Sell
-147,771
Closed -$163K – 3308
2025
Q2 		$163K Buy
+147,771
New +$166K ﹤0.01% 2487
2025
Q1 		– Sell
-157,953
Closed -$246K – 3010
2024
Q4 		$246K Buy
157,953
+41,594
+36% +$120K ﹤0.01% 2292
2024
Q3 		$427K Buy
116,359
+106,359
+1,064% +$372K ﹤0.01% 1975
2024
Q2 		$33.1K Sell
10,000
-123,576
-93% -$520K ﹤0.01% 2463
2024
Q1 		$569K Buy
+133,576
New +$562K ﹤0.01% 1882

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's PYXS Position: Q1 2026 in Review

Marshall Wace reduced its Pyxis Oncology (PYXS) stake by 9.1% in Q1 2026, selling an estimated $53.3K and leaving 354,417 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Marshall Wace first reported a position in PYXS in Q1 2024 and has held it in 7 quarters since. The position peaked at $569K in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Marshall Wace held 354,417 shares of Pyxis Oncology worth $517K as of Q1 2026.
  • Marshall Wace sold 35,347 Pyxis Oncology shares in Q1 2026, an estimated $53.3K.
  • Pyxis Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2436 holding.
  • Marshall Wace first reported a position in Pyxis Oncology in Q1 2024 and has held it in 7 quarters since.
  • Marshall Wace's Pyxis Oncology position peaked at $569K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.